SCHEMBL7032054

SCHEMBL7032054

O=C(OCc1ccccc1)c1cc2[nH]c(=O)n(Cc3ccccc3)c(=O)c2s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.52
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 3/20 0.42
MAPT P10636 3/20 0.42
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP12 P39900 2/20 0.41
MMP1 P03956 1/20 0.41
KMT2A Q03164 3/20 0.41
BLM P54132 1/20 0.41
ADRA1B P35368 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC1 Q13547 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A3 Q01959 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
ERCC5 P28715 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7025482 0.86 ALDH1A1 (0.52) ALDH1A1KDM4ESMN1; SMN2HPGDPOLB
SCHEMBL6258644 0.82 MMP13 (0.54) MMP13ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL7035476 0.80 MAPT (0.53) ALDH1A1KDM4ESMN1; SMN2HPGDMAPT
SCHEMBL7032058 0.78 MMP13 (0.53) MMP13ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL6259959 0.77 MMP13 (0.49) MMP13ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL7035477 0.76 MMP13 (0.51) MMP13ALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL6258383 0.76 MMP13 (0.46) MMP13ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL6258325 0.76 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2HPGDPOLB
SCHEMBL6473178 0.75 KDM4E (0.49) MMP13ALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL6260515 0.73 MMP13 (0.46) MMP13ALDH1A1KDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370562-A1 THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS Warner-Lambert Company LLC (US) 2003-12-17 EP disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 MMP13 1/4885ALDH1A1 812/4885KDM4E 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.